Show simple item record

dc.contributor.authorLamarca, Angela
dc.contributor.authorPalmer, D.
dc.contributor.authorWasan, H. S.
dc.contributor.authorRoss, P.
dc.contributor.authorMa, Y. T.
dc.contributor.authorArora, A.
dc.contributor.authorFalk, S.
dc.contributor.authorGillmore, R.
dc.contributor.authorWadsley, J.
dc.contributor.authorPatel, K.
dc.contributor.authorAnthoney, A.
dc.contributor.authorMaravellas, A.
dc.contributor.authorWaters, J. S. C.
dc.contributor.authorHoobs, C.
dc.contributor.authorMacdonald, T.
dc.contributor.authorRyder, D.
dc.contributor.authorRamage, J.
dc.contributor.authorDavies, L.
dc.contributor.authorBridgewater, J. A.
dc.contributor.authorValle, Juan W
dc.date.accessioned2023-01-24T10:32:19Z
dc.date.available2023-01-24T10:32:19Z
dc.date.issued2022en
dc.identifier.citationLamarca A, Palmer D, Wasan HS, Ross P, Ma YT, Arora A, et al. Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial. Annals of Oncology. 2022 Sep;33(7):S564-S5. PubMed PMID: WOS:000866211600054.en
dc.identifier.doi10.1016/j.annonc.2022.07.082en
dc.identifier.urihttp://hdl.handle.net/10541/625948
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.07.082en
dc.titleQuality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record